RVL Pharmaceuticals (NASDAQ: RVLP), a specialty pharmaceutical company focused on the commercialization of UPNEEQ(R) (oxymetazoline hydrochloride ophthalmic solution) (“UPNEEQ”), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults, has announced a prepackaged reorganization of some of its subsidiaries. Those subsidiaries include RevitaLid Pharmaceutical Corp., RVL Pharmaceuticals Inc. and RVL Pharmacy, LLC. According to the announcement, a change of control transaction agreement was reached with their sole secured lenders, funds managed by Athyrium Capital Management (“Athyrium”) and other key stakeholders. The transaction will be made through through prepackaged bankruptcy cases that have begun in the U.S. Bankruptcy Court for the District of Delaware. The agreement calls for the RVL subsidiaries to focus on reducing debt, streamlining operations and maintaining jobs as they position themselves under new ownership. RVL will begin to wind down remaining operations of the company and other subsidiaries.
The company noted that its public equity will be cancelled once the wind-down is complete sometime next year. Funds managed by Athyrium will exchange outstanding debt into equity of a newly formed entity that will either (1) directly hold 100% of the equity interests of Revitalid Pharmaceutical, Corp., which is currently an indirect wholly owned subsidiary of the company, or (2) indirectly hold 100% of the equity interests of RVL Pharmaceuticals Inc., which is currently a wholly owned subsidiary of Revitalid Pharmaceutical, Corp. and the direct parent of RVL Pharmacy, LLC. “This is a significant step forward in securing RVL’s future, ensuring we continue to meet the demands of our patients while also executing our long-term growth strategy,” said RVL Pharmaceuticals CEO and board chair Brian Markison in the press release. “As we move forward, we remain committed to realizing the full commercial potential of UPNEEQ.”
To view the full press release, visit https://ibn.fm/3R43W
About RVL Pharmaceuticals plc
RVL Pharmaceuticals plc is a specialty pharmaceutical company focused on the commercialization of UPNEEQ (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults. UPNEEQ is the first nonsurgical treatment option approved by the FDA for acquired blepharoptosis. For additional information about this company, please visit www.RVLPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to RVLP are available in the company’s newsroom at https://ibn.fm/RVLP
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
BioMedWire is powered by IBN